Adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: A systematic review

Boer, J N de; Boot, Erik; Gils, Lissa van; Amelsvoort, Thérèse van; Zinkstok, Janneke

doi:10.1002/ajmg.a.61324

Cited by 12 publications

(13 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, clozapine or quetiapine in combination with the valproic acid was suggested to be effective in the management of psychosis. A recent systemic review, which examined the adverse effects of antipsychotic medications in patients with VCFS, concluded that a causal relation between antipsychotic medication and the reported adverse effects could not be established in the majority of cases as the syndrome itself can present with antipsychotic‐related side effects such as seizures and cardiac pathology 3 . Lithium is known to be effective and well tolerated in pediatric patients for treatment of bipolar 1 disorder 4 …”

Section: Discussionmentioning

confidence: 99%

Recurrent mania in an adolescent with velocardiofacial syndrome and treatment challenges

2020

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Recurrent mania in an adolescent with velocardiofacial syndrome and treatment challenges

2020

View full text Add to dashboard Cite

“…While there has been some suggestion to avoid certain psychotropic medications for individuals with 22q11.2 deletions (due to increased risk for seizures), 59 other studies have suggested that further evidence is needed before making psychotropic medication recommendations solely based on the presence of the CNV. 60,61 Currently, medication decisions should be made by a psychiatrist based on the current symptoms. Over-attribution of genetics (i.e., Feeling that the CNV determined their psychiatric illness and that it is "genetically ingrained"…”

Section: Discussing the Role Of The Cnv In The Etiology Of Psychiatri...mentioning

confidence: 99%

“…Exploring the role of psychotropic medication(s) and encouraging appropriate consultation with a psychiatrist may also be helpful. While there has been some suggestion to avoid certain psychotropic medications for individuals with 22q11.2 deletions (due to increased risk for seizures), 59 other studies have suggested that further evidence is needed before making psychotropic medication recommendations solely based on the presence of the CNV 60,61 . Currently, medication decisions should be made by a psychiatrist based on the current symptoms.…”

Section: Scenario 2: Identifying a Psychiatric Susceptibility Cnv In ...mentioning

confidence: 99%

Psychiatric genetic counseling for people with copy number variants associated with psychiatric conditions

2022

View full text Add to dashboard Cite

22q11.2 deletion is one of the most well-known copy number variants (CNVs) associated with developing a psychiatric condition (e.g., schizophrenia), but there is a growing list of other CNVs which also confer substantial risk for developing psychiatric conditions. With increased use of chromosome microarray and exome sequencing, the frequency with which these CNVs are detected is increasing. While individuals with such CNVs often receive genetic counseling, research shows that associated psychiatric conditions are less often addressed-clinicians tend to focus on the nonpsychiatric manifestations of the CNV. This represents an important service gap for people with these CNVs and their families, as research shows that not only do these families want genetic counseling about psychiatric illness, it can also produce meaningful positive outcomes for people, including increases in empowerment, and selfefficacy. Therefore, there is a need to ensure that individuals with psychiatric condition-associated CNVs are being counseled about these manifestations of their condition in a way that can promote the best outcomes. In this paper we describe the process of providing genetic counseling in two clinical scenarios in which a psychiatric susceptibility CNV is identified: (1) in an individual who has not been diagnosed with a psychiatric condition and (2) in an individual with an established psychiatric condition.

show abstract

“…Similar to our recommendations for children, management and treatment should be planned in the context of any cognitive or physical comorbidities, and pharmacotherapy should be based on a consideration of any medical comorbidities and sensitivity to adverse effects [ 44 •• ]. For 22q11.2DS a literature is building on psychopharmacotherapy effectiveness and side effects [ 44 •• ], particularly so for the administration of antipsychotics [ 52 , 53 , 54 ], but further research is needed for other CNVs.…”

Section: Clinical Evaluationmentioning

confidence: 99%

Clinical evaluation of patients with a neuropsychiatric risk copy number variant

Chawner

2021

Current Opinion in Genetics & Development

View full text Add to dashboard Cite

Several copy number variants (CNVs) have been identified to confer high risk for a range of neuropsychiatric conditions. Because of advances in genetic testing within clinical settings, patients are increasingly receiving diagnoses of copy number variant genomic disorders. However, clinical guidelines surrounding assessment and management are limited. This review synthesises recent research and makes preliminary recommendations regarding the clinical evaluation of patients with neuropsychiatric risk CNVs. We recommend multi-system assessment beyond the initial referral reason, recognition of the potential need for co-ordinated multidisciplinary care, and that interventions take account of relevant multimorbidity. The frequently complex needs of patients with CNVs across the life-course pose challenges for many health care systems and may be best provided for by the establishment of specialist clinics.

show abstract

Adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: A systematic review

Cited by 12 publications

References 56 publications

Recurrent mania in an adolescent with velocardiofacial syndrome and treatment challenges

Recurrent mania in an adolescent with velocardiofacial syndrome and treatment challenges

Psychiatric genetic counseling for people with copy number variants associated with psychiatric conditions

Clinical evaluation of patients with a neuropsychiatric risk copy number variant

Contact Info

Product

Resources

About